Since the brain's gray matter (GM) 
INTRODUCTION
Proton MR spectroscopy ( 1 H-MRS) provides unique specificity to pathological processes in the brain by quantifying metabolic surrogates such as: N-acetylaspartate (NAA) for neuronal integrity; creatine (Cr) for glial proliferation; choline (Cho) for membrane turnover; and myo-inositol (mI) for astrogliosis (1, 2) . Its sensitivity to their concentration changes, however, is low mainly due to: (i) The intrinsic low voxel signal-to-noise ratios (SNR) that reduce its reproducibility (3, 4) ; (ii) variations in cerebrospinal fluid, white and gray matter (CSF, WM, GM) composition in each voxel. Since metabolite concentrations in GM differ from WM with virtually none in the CSF (5) , and since pathologies may affect these tissue types differently (6, 7) , variations in the voxel compositions diminish the statistical power to detect changes (8) . These partial volume effects are exacerbated by volume of interest (VOI) misregistration in longitudinal and cross-sectional studies.
Unfortunately, these SNRs and partial volume effect issues are inextricable. For a given instrumental setup and scan time, addressing the SNR by increasing voxel size comes at the expense of larger partial volumes and vice versa (9, 10) . Furthermore, the thin 1-4 mm tortuous GM ribbon (11) makes it difficult to place the~2 Â 2 Â 2 cm 3 typical single-voxel 1 H-MRS volumes in "pure" WM and therefore almost impossible to obtain "pure" GM voxels. In addition, single-voxel 1 H-MRS precludes verification of diffuse (multi-focal) metabolic changes that characterize common neurological disorders (1, 2) . Surprisingly, even though multi-voxel 1 H MR spectroscopic imaging ( 1 H-MRSI) can yield much higher (~1 cm 3 ) spatial resolution, its analysis is often done on a voxel-by-voxel basis (12) and the consequences of tissue partial volume on its precision (reproducibility) are to the best of our knowledge not discussed in the literature.
The misregistration, SNR and partial volume issues can be substantially reduced by combining absolute 1 H-MRSI metabolic quantification with anatomical high-spatial resolution (~1 mm 3 ) MRI that accompanies it. Using freely available segmentation software, WM/GM/CSF masks can be produced and overlaid on the 1 H-MRSI grid to yield their contents in each voxel (13, 14) . This information can yield global WM and GM metabolite concentrations by modeling the 1 H-MRSI signal from each voxel as a linear combination of their contributions. Thus, at the cost of averaging out regional metabolic variations (15) -a reasonable tradeoff in diffuse disorders -analysis of all voxels can dramatically improve SNR while also accounting for partial volume effects. In this paper, we show that this approach improves sensitivity to diffuse/global differences that predominate in either WM or GM and estimate the metabolite concentration variations that can occur when GM and WM partial volumes are not accounted for.
MATERIALS AND METHODS

Human subjects
Eighteen (12 women, 6 men; range 19-57 y) healthy individuals were enrolled. Their healthy status was determined by selfreported negative answers to disqualifying neurological and MR contraindications before the scan and an unremarkable MRI determined by a neuroradiologist afterwards. All were briefed on the procedure and provided an Institutional Review Board approved written informed consent.
MR data acquisition
All experiments were carried out on a 3 T scanner (Trio, Siemens AG, Erlangen, Germany) with a TEM3000 circularly-polarized transmit-receive head-coil (MR-Instruments, Minneapolis, MN, USA) capable of delivering a 1 kHz B 1 field to the human head with~1.5 kW of radio-frequency (RF) power. For 1 H-MRSI VOI image-guidance and tissue segmentation, 160 1-mm thick slices were acquired by sagittal Magnetization Prepared RApid Gradient Echo (MP-RAGE): TE/TI/TR = 2.6/800/1360 ms, 256 Â 256 mm 2 field of view, 256 Â 256 matrix. They were reconstructed in axial, sagittal and coronal planes at 1 mm 3 isotropic resolution and angled to render the genu and splenium of the corpus callosum in the same horizontal plane as shown in Figure 1 .
Our chemical-shift imaging-based (CSI) automatic procedure then adjusted the full second order shims in 3-5 minutes (16) . Next, a 10-cm anterior-posterior (AP) Â 8 cm left-right (LR) Â 4.5 cm inferior-superior (IS) = 360 cm 3 VOI was image-guided over the corpus callosum as shown in Figure 1 . It was excited with a TE = 35 ms PRESS in three second-order Hadamard-encoded 1.5 cm thick slabs (for a total of 6 slices) and interleaved along the IS direction every TR = 1800 ms (Fig. 1a) for optimal SNR and spatial coverage (17) . It also enabled a strong 6 mT/m slice-select gradient for the 5.12 ms Hadamard PRESS 90 RF pulses, reducing the 1.56 ppm (~200 Hz) chemical shift between NAA and mI to just an~0.6 mm displacement (18) . The slices were partitioned with 16 Â 16 CSI over a 16 Â 16 cm 2 FOV to yield
given the full-width at half-max of the 2D point spread function (19) (20) (21) ]. The 8 Â 10 cm VOI was defined with two 11.2 ms numerically optimized 180 RF pulses (4.5 kHz bandwidth) under 1.34 (LR) and 1.1 mT/m (AP) gradients to yield 8 Â 10 Â 6 = 480 voxels. The PRESS 180 RF pulses were calibrated to ensure that their transition bands fell outside the VOI in voxels that were subsequently discarded during post-processing. The MR signal was acquired for 256 ms at 1 kHz bandwidth. At two averages, the 1 H-MRSI took 34 min.
Voxel volumetry
Each subject's MP-RAGE images were segmented using SPM2 [Wellcome Department of Cognitive Neurology, Institute of Neurology, Queen Square, London, UK (22, 23) ] into CSF, WM and GM masks in~15 min on a Core i7 class workstation. These were co-registered with the 1 H-MRSI grid using in-house software that computed their volume in every j-th voxel of the k-th subject (V jk GM , V jk WM , V jk CSF ) in~5 seconds as shown in Figure 2 . Since 1 H-MRSI and MRI were acquired in the same frame of reference, no deformations or shearing transformations were needed.
Metabolic quantification
1 H-MRS data were processed offline using in-house software. Data were voxel-shifted to align the NAA grid with the VOI, then Fourier transformed in time, AP and LR directions and Hadamardtransformed along the IS dimension. Each spectrum was frequency-aligned and zero-order phased in reference to the NAA peak. Relative levels of the i-th (i = NAA, Cr, Cho, mI) metabolite in the j-th ( j = 1. . .480) voxel in the k-th (k = 1. . .18) subject S ijk were estimated from their peak area using SITools-FITT spectral modeling software (24) . It used the full lineshapes of aspartate, glutamate, glutamine, Cho, Cr, mI, NAA and taurine as model functions obtained with the GAVA simulation program for our pulse sequence (25) . This process, which takes about 30 min, uses a priori spectral information and includes non-parametric baseline signal component characterization and Lorenz-Gauss lineshape assumption. Analysis of this baseline modeling showed that for spectra with 5 Hz linewidth, the mean errors of the fit were 3.4%, 2.3% and 2.8% for NAA, Cr and Cho, respectively (26) . The S ijk -s were H spectra matrix from the VOI on (b) on common 1.7 -3.7 ppm and intensity scales. Bottom: (d) The 4 spectra from the 2 Â 2 white grid on (b) indicated by the black arrows on (c) are expanded for greater detail, superimposed with the fitted waveform used for quantification in Equation [1] . Note the SNR and spectral resolution from these 0.75 cm 3 voxels in~30 minutes of acquisition and the fit quality.
scaled into absolute amounts Q ijk against a 2 L sphere of C i vitro = 12.5, 10.0, 3.0 and 7.5 mM NAA, Cr, Cho and mI in water at physiological ionic strength to load the coil and VOI size and position similar to in vivo studies to approximate a similar B 1 profile up to the intrinsic differences between the phantom and the head due to tissue-RF field interactions at 3 T:
where V is the voxel volume (0.75 cm 3 ); S ijR is the sphere voxel metabolite signal; and P k 180 and P R 180 are the RF power for a non-selective 1 ms 180 inversion pulse on the k-th subject and reference. To account for different relaxation times in vivo (T 1 vivo , T 2 vivo ) and in the phantom (T 1 vitro , T 2 vitro ), the Q ijk in were corrected for each metabolite i using Equation [2] (27):
Global VOI concentrations Individual age-adjusted T 2 vivo WM and GM values for NAA, Cr and Cho were calculated using published formulae (28) . For the whole VOI, we used their WM and GM values weighted by each tissue volume fraction in that individual's VOI (sum of their fractions in all the voxels). Their mean T 2 vivo values over all 18 subjects were 350, 174 and 251 ms. T 2 vivo = 200 ms was used for mI with no GM/WM or age difference (29) . Since no significant GM/WM or age differences were reported for T 1 vivo at 3 T, we used 1360, 1300, 1145 and 1170 ms (29, 30) . The corresponding values measured in the phantom were T 2 vitro = 483, 288, 200, 233 ms and T 1 vitro = 605, 336, 235 and 280 ms. The average whole-VOI tissue concentration for each metabolite C ik was obtained by Equation [3] : CSF for the analysis of Equations [3] and [4] . Right: Histograms of the % of the total number of 8,640 voxels (18 subjects Â 480 voxels each) containing a given fraction of GM, WM and CSF at 5% bin resolution. Note that even at this relatively high spatial resolution (0.75 cm 3 ) , it is hard to get a "pure", i.e. > 95% WM voxel, a requirement satisfied by less that 10% of all voxels and nearly impossible (<1%) to get one that is > 95% GM.
This sum has the advantage of (number of voxels) ½ % 22 fold less variance than individual elements and consequently, expected to yield better precision, as described by Kreis (4) .
Global WM and GM concentrations
Since CSF does not contribute to the 1 H-MRS signal, the i-th metabolite amount in the j-th voxel of the k-th subject can be modeled as a sum of two (GM, WM) compartments by Equation [4] :
; [4] where C ik WM , C ik GM are the unknown global WM and GM concentrations of the i-th metabolite in the k-th subject, and f i GM , f i WM are calculated by Equation [2] using GM T 2 vivo s of 275, 157, 241 and 200 ms for NAA, Cr, Cho and mI, and 400, 185, 258 and 200 ms for WM (28, 29) . The corresponding T 1 vivo s , T 2 vitro s and T 1 vitro s, are the same as for Equation [3] . For each volunteer, Equation [4] comprises a set of 480 over determined equations for C ik WM and C ik GM that can be solved with least-squares optimization that minimizes the total error as per Equation [5] 
for each metabolite i and patient k. Since the brain's GM and WM spatial heterogeneity is on a scale smaller than the 1 cm 3 of the voxels, the j = 1, . . . , 480 V jk GM and V jk WM coefficients (480 equations) are independent, guaranteeing a non-degenerate solution.
RESULTS
Our shim produced a consistent 22 AE 3 Hz FWHM VOI water linewidth. An example of the VOI size, position and 1 H-MRSI is shown in Figure 1 . The SNRs in 8,640 voxels (18 subjects Â 480 voxels each) were: NAA = 30 AE 6, Cr = 15 AE 3, Cho = 13 AE 2 and mI = 8 AE 1 (mean AE standard deviation) estimated as peak height divided by twice the root-mean-square of the noise. The metabolites' voxel FWHM linewidth was 6.6 AE 1.1 Hz. The average VOI composition was 9 AE 2% CSF, 39 AE 2% GM and 52 AE 3% WM. Its tissue fraction was 43 AE 2% GM and 57 AE 2% WM. Analysis of the individual voxels' GM, WM and CSF composition (Fig. 2) reveals that even at this relatively high spatial resolution, less than 1% of the voxels can be considered "pure" (95% or greater) GM and under 10% "pure" WM, as shown in Figure 2 . Of the 8640 voxels in the 18 VOIs, about 86% contained less than 10% CSF (Fig. 2) .
Global VOI, WM and GM metabolites' concentrations from our 18 subjects are compiled in Table 1 with their least-squares errors (E ik in Equation [5] ) as quantitative "goodness of the fit" metric. To demonstrate their different GM and WM distributions and sensitivity gain from the segmentation process, the concentrations are also plotted in Figure 3 . The absolute-valued NAA residual error map obtained by subtracting the synthesized NAA map (Q ijk calculated from Equation [4] for each voxel using its V jk GM and V jk WM and the global least-squares C ik WM , C ik GM ) from the experimental one is Table 1 . Absolute mM whole-VOI tissue concentrations (VOI), global WM and GM concentrations (C WM , C GM ) of the NAA, Cho, Cr, mI for the 18 subjects using Equations [3] , [4] and least-squares fitting. The global fitting error (E ik in Equation A. TAL ET AL.
wileyonlinelibrary.com/journal/nbm shown in Figure 4 . Also shown is the normal probability plot for the E ik ,s for the whole VOI for that metabolite and patient for visual assessment of the statistical normalcy of the errors.
DISCUSSION
The problem of inferring WM and GM-specific metabolite concentrations has been addressed in many 1 H-MRS studies. Although single voxel 1 H-MRS studies often attempt to circumvent this issue by placing the VOI in "mostly" WM or GM (31), partial volume effects quantified in Figure 2 , SNR limitations, and misregistration all introduce quantification errors. A remedy in 1 H-MRSI is to apply linear regression to the metabolites' concentrations and either the GM or WM voxel volume fractions (13, (32) (33) (34) (35) (36) (37) . In such linear model, the voxels' signals are assumed to be of the form given by Equation [4] , while the constraint V jk GM + V jk WM + V jk CSF = V is addressed by -
; the voxels' signals are then fitted to a straight line of the form:
In contrast, minimizing the error given by Equation [5] seeks to fit the data to a 2D plane constrained to pass through the origin: Q ijk = 0 for V jk WM = V jk GM = 0. While both approaches are equivalent for a noiseless signal, once a random normally distributed error term (e ijk ) is added to the model (Equation [4] ), its division by (V-V jk CSF ) raises the variance of the statistical estimators for C GM , C WM (38) by the ratio of the variances of the undivided and divided errors as shown in Equation [4] :
This effect can be mitigated by increasing the number of voxels and by excluding all those above a certain threshold for V jk
CSF
. This, however, may become prohibitive for smaller structures or 2D MRSI data. It can be avoided altogether by employing a 2D constrained fitting procedure (Equation [5] ), where division by V-V jk CSF is unnecessary. Two other studies applied linear regression in sub-structures: e.g. the right temporal lobe (33, 34) . While concentrations variation among structures is well documented (13, 15) , arguably in diffuse (or multi-focal) diseases affecting the whole brain, changes are of interest not absolute magnitudes. Applying Equation [4] to the entire heterogeneous VOI therefore, should not detract from the method's power to detect this change and only serves to increase the sensitivity (3, 4) .
While the improved SNR of this approach is reflected in small 7-15% coefficients of variations (CV = standard deviation/mean) of the C i GM s and C i WM s in Table 1 , the partial volume confounds are more subtle and will be treated separately. First, random GM and WM voxel composition due to either (i) contamination of an intended "pure" tissue or (ii) misregistration in different exams may lead to variations in the MRS signal, reducing statistical power to detect pathology-induced changes. Second, these variations also decrease the ability to detect changes specific to one tissue type but not the other.
Quantification errors from partial volume variation
To estimate the error introduced by WM and GM voxel composition variations due to misregistration (scenario (i) above), let Figure 3 . Box plots showing the first, second (median) and third quartiles (box) and AE 95% (whiskers) of the non-tissue specific WM and GM NAA, Cho, Cr and mI whole-VOI concentration distributions superimposed with their respective dot plots showing the concentrations in each for the 18 healthy volunteers. Note the differences between WM and GM tissue-specific concentration differences that can modulate the non-specific VOI concentration depending on their partial-volume, as described by Equations [8] and [9] V WM , V GM and V be the WM, GM and total voxel (assume for simplicity no CSF: V = V WM + V GM ) and C WM , C GM the tissue metabolite concentration. This metabolite's 1 H-MRS signal from that voxel will be proportional to its amount: Q = V WM.
GM . Ideally, for a pure WM, one would have V GM = 0. However, if the voxel contained unintentional V GM 6 ¼ 0, then its signal would differ by a multiplicative "fractional error" factor d:
Using the median C GM = 6.7 mM and C WM = 4.7 mM for Cr (often used as an internal standard in 1 H-MRS) from Figure 3 and assuming a commonly encountered V GM /V = 0.2 -difficult to avoid for large(r) single-voxel studies (Fig. 2) -yields d %  1.1 . Thus, the apparent Cr C WM would be biased~10% upwards.
Note that Equation [8] holds true for any change from an initial V GM /V on subsequent measurements (scenario (ii) above). Specifically, an easily incurred 20% WM and GM voxel composition difference due to misregistration can lead to quantification variations of the order of 10% for absolute quantification and even more for metabolite ratios (39) .
WM and GM specificity loss due to partial volume variation
The MRSI signal of each metabolite in every voxel represents the sum of its GM and WM contributions. However, if a diffuse disease affects the concentration of a metabolite predominantly in GM, e.g. in cognitive disorders or WM, e.g. in leukodystrophies, these tissuespecific changes will be "diluted" and modulated by the signal from the other unaffected tissue fractions, reducing the contrast between patients and controls and, consequently, the sensitivity.
To estimate the magnitude of this contrast loss, consider a diffuse disease that alters only a metabolite's GM concentration C GM by an amount ΔC
GM
. Denoting that metabolite's overall (unsegmented) concentration in controls by C ctrl , its concentration in patients C pts will be: A. TAL ET AL.
wileyonlinelibrary.com/journal/nbm
where the metabolite (i) and patient (k) indices were omitted for brevity and 
The global non tissue-specific concentration of a metabolite in question C ctrl is given by the weighted average of its tissue concentrations
and f WM VOI ≤ 1 are the VOI GM and WM fractions. Thus, C ctrl , C pts are also normally distributed:
The number of patients needed to observe this difference with the same statistical power (80%) and significance level (0.05) as before has now increased:
[12]
For example, in the VOIs studied herein, the WM:GM % 3 : 2. Given whole-brain WM : GM of~0.7 (40, 41) Equation [13] represents a general rule of thumb for any sufficiently large heterogeneous VOI: A linear regression like the one described can increase a study's statistical power two-fold.
Applications
The method described in this review is applicable in the following clinical scenarios: (i) In diseases with a known diffuse component such as traumatic brain injury, multiple sclerosis, encephalopathies, late stage dementias and HIV-associated neurological disorder, tumours and leukodystrophies (in those diseases with focal centers, the method can be used to observe the diffuse component in the adjacent normal appearing tissue); (ii) In focal disease where a hypothesis tests for diffuse involvement of normal-appearing tissue; (iii) In focal disease known to advance to diffuse (e.g. dementias) in order to time the progression; and (iv) in both diffuse and focal diseases to assess global drug effects.
Caveats
Global WM and GM quantification is subject to several limitations arising from an approach geared to maximize sensitivity at the expense of localization. (i) It is insensitive to focal changes that may occur in specific small brain regions. (ii) Since metabolites' concentrations are assumed to be the same in a given tissue type (GM or WM), only uniform diffuse changes (all increases or all decreases) are detectable. Large changes in concentrations between brain structures within a particular tissue -e.g. between the cerebrum and cerebellum (42) -will be averaged out, which will diminish the approach's statistical power. This limitation, however, can be relaxed since, although we used 480 equations (Equation [4] ) to deduce C WM , C GM , only two equations are actually necessary. The other 480 -2 = 478 merely increase the robustness. Therefore, if the VOI is divided into sub-regions of at least 2 voxels each, their local C WM and C GM could be determined on a spatial scale only slightly coarser than the acquisition grid. (iii) Long post-processing (~45 min/subject) may impede clinical application. Finally, (iv) although our VOI covered substantially more brain than most single voxel or 2D 1 H-MRSI studies, it excluded most of the cortex and infratentorial brain. Given the average brain GM and WM volumes of~700 cm 3 and 500 cm 3 (41) our VOI contained 20% of the total GM (including cortical and most of the deep structures) and 40% of the WM. The cortical periphery was excluded due to technical challenges of cortical spectroscopy, including lipid contamination and shimming artifacts. However, given a multivoxel sequence capable of overcoming these limitations, the cortex would make an excellent candidate for investigation using this technique: the tortuous thin (1-4 mm) GM cortical strip is often impossible to observe directly with multivoxel spectroscopy due to the large spectroscopic voxels and the partial volume effects from the adjacent white matter. A linear regression-based method such as the one described herein, in combination with the excellent performance of most segmentation algorithms for the other regions of the brain, can be used to obtain cortex-specific spectra. Given the functional and cognitive importance of the cortical GM, we anticipate the outlined approach to become a useful tool for probing cortical GM metabolite concentrations.
